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Raman spectroscopy involves the interaction of light with the molecular vibrations and therefore can
provide information about molecular structure, tissue composition and changes in its environment. We
explored whether Raman spectroscopy can reliably distinguish mammary tumors from normal mammary
tissues and other pathological states in mice. We analyzed a large number of Raman spectra from the tumor
and normal mammary glands of mice injected with 4T1 tumor cells, which were collected using a high-
resolution (less than 4 cm−1) Raman spectrometer at a fixed (785 nm) laser excitation wavelength and with
60 mW of laser power. The spectra of normal and tumor mammary glands showed consistent differences in
the intensity of certain Raman bands and loss of some bands in the tumor spectra. Multivariate statistical
methods – principal component analysis (PCA) and discriminant functional analysis (DFA) – were used
to separate the data into different groups of mammary tumors, mastitis, lymph nodes contralateral and
tumor-cell-injected sides, and normal contralateral and tumor-cell-injected sides. We demonstrate that this
spectroscopic technique has the feasibility of discriminating tumor and mastitis from normal tissues and
other pathological states in a short period of time and may detect tumor transformation earlier than the
standard histological examination stage. Copyright  2006 John Wiley & Sons, Ltd.
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INTRODUCTION
Raman spectroscopy is widely used in nondestructive
biochemical analyses. Recently it has been applied for
the detection of different types of cancers.1 – 4 Raman
spectroscopy has also been used for classification of tissues
into cancerous and precancerous stages.5,6 This spectroscopic
technique has several advantages over Fourier-transform
infrared spectroscopy (FTIR)7 because any wavelength can
be used as a source of excitation and it provides more
detailed information about the biochemical components
of the sample. Another disadvantage of FTIR for tissue
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examination is the strong absorption of IR radiation by the
large water content of the tissue. In Raman spectroscopy,8
a tissue sample is irradiated with a laser which interacts
with the various molecular components of the tissue. This
interaction of light with the molecular vibrational modes
results in scattered light with a unique shift in the frequency
(Raman shift) and thereby provides information about the
molecular structure and composition of the sample.9 Each
peak position in the Raman spectrum represents a vibrational
mode of a specific group (such as -CH2, -CH3, -NH, peptide,
etc.) of a biomolecule present in that particular environment
of the tissue. The peak height (strictly the area under the
peak) is directly related to its concentration in a tissue.
Transformations of normal tissue into a tumor or any
other state (e.g. inflammatory) are due to changes in the
Copyright  2006 John Wiley & Sons, Ltd.
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concentration of the specific biomolecules. These changes
are in turn reflected in the Raman vibrational spectra.
One of the main foci of cancer research is to understand
the molecular changes during neoplastic transformations
and translate them into diagnostic and therapeutic tools.
The ability of Raman spectroscopy to uniquely map the
molecular changes in transformed tissues can be exploited
for rapid detection of neoplastic transformation with high
specificity and sensitivity compared to other conventional
methods. Moreover, because it is noninvasive10 and requires
no sample preparation, and also because the Raman bands of
water are quite week, Raman spectroscopy has the potential
for real-time in vivo cancer diagnosis applications11,12 using
an optical-fiber probe.13
Earlier breast studies based on small sample sets have
identified some trends in the spectra.3,14,15 Here we sought to
determine the ability of Raman spectroscopy to differentiate
normal mouse breast tissues from those with cancer on a very
large data set. We further investigated whether Raman spec-
troscopy can be used to detect metastases before they are evi-
dent histologically and can provide some information about
the transformation of normal tissues into malignant ones. We
analyzed 650 Raman spectra from mouse mammary tumors
and normal mammary glands along with other pathological
states or tissue types. Multivariate statistical techniques sep-
arated spectra of tumors and mastitis from normal mammary
gland tissues and other pathological states.
EXPERIMENTAL
Animals and cell line
Female BALB/c mice of 6–8 weeks (The Taconic Farm,
Germantown, NJ) were used in our experiments. All
animals were treated humanely and in full compliance
with the National Institutes of Health (NIH) regulations
and institutional guidelines as approved by the Animal
Investigation Committee of the Wayne State University
Department of Laboratory Animal Resources. The 4T1
mouse mammary tumor cell line was used to induce tumor
formation. These cells were grown in Dulbecco’s Modified
Eagle’s Medium (DMEM) supplemented with 10% fetal
bovine serum.
We used a Renishaw RM 1000 Raman microscope-
spectrometer with the 785 nm near-infrared (NIR) excitation
wavelength16 to record the Raman spectra. We selected this
excitation wavelength to avoid the background fluorescence
caused by shorter excitation wavelengths. Best spectral
features14 are obtained with excitation wavelengths between
782 and 830 nm.
Induction of mammary tumors
Mammary tumors were generated in 11 BALB/c mice by
orthotopic injection of 1 ð 105 4T1 cells suspended in the
DMEM medium into a mammary fat pad (one side only).
Primary tumors were detected palpably within 10–14 days.
Fourteen days after the injection of tumor cells, the mice
were sacrificed, one at a time to get data from fresh tissues
without any preservation from the normal mammary tissues,
mammary tumors, and lymph nodes, from both tumor-cell-
injected and contralateral sides. The details are given in
the Table 1. Each sample was immediately divided into two
halves, one was used for the Raman spectroscopy and the
other was immediately fixed in 10% formalin for histological
examination. Samples included 16 tissues that were tumors,
12 that appeared normal and 10 lymph nodes from the
Table 1. Tissue identification from pathology studies
Tissue name A B C D E F G
Mouse1 M1 T1 LN1 M2 LN2 T2 –
Mouse2 M1 T LN1 M2 LN2 – –
Mouse3 M1 T1 M2 LN2 T T2 –
Mouse4 M1 T LN1 M2 – – –
Mouse5 M1-MAS T LN1-MASa M2-MAS LN2-MASa – –
Mouse6 M1 T1 LN1-MASa M2-MAS LN2-MASa T2 –
Mouse7 M2 T M2 M1 LN1 – –
Mouse8 M1 T LN1 M2 C LN2 M2 – –
Mouse9 T1 M1 LN1 M2 LN2 T2 T3
Mouse10 M1 T LN1 M2 LN2 – –
Mouse11 M1 T LN1 M2 LN2 – –
M1 D Mammary gland from the tumor-cells-injected side (2 in data set).
M2 D Mammary gland from the contralateral side (1 in data set).
T D Tumor (T1 D first tumor, T2 D second tumor, etc.) (3 in data set).
LN1 D Lymph nodes from the tumor-cells-injected side (5 in data set).
LN2 D Lymph nodes from the contralateral side (4 in data set).
MAS D Mastitis (6 in data set).
a Samples not used in data analysis.
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side injected with tumor cells. From the contralateral side,
13 samples of mammary tissues and 8 lymph nodes were
harvested. From each tissue, 12 or more Raman spectra were
collected from random locations, 2 of them were collected
within 30 min after the mouse tissues were harvested
and 10 were collected later that day during the tissue
mapping studies. After the Raman spectra were obtained
the samples used to generate the Raman spectra were fixed
in a 10% formalin solution and submitted for histopathologic
validation to further confirm the pathological states of these
tissues. All tissues were examined by a senior pathologist
and here we use her categorization.
Raman spectroscopic measurements and analysis
Organs not being uniform contain several types of tissues
and cells, e.g. blood, lymph, fibrous tissue, in addition to
the parenchymal tissue specific to that organ. Some of these
elements generate noise or fluorescence17 when excited, and
therefore can interfere18,19 with the Raman signal. The laser
beam was focused on the tissue with a spot size of 5 µm
radius using a 50ð objective, and spectra were collected
in the backscattering geometry with a 10 s integration time
over a spectral range 600–1800 cm1. In order to maximize
the Raman spectral information of a tissue, we performed
Raman mapping studies by selecting five different spots in
a 100 µm ð 100 µm area on a tissue. Two mapping studies
were performed for each tissue. Each spectrum represents a
different point of a tissue and each point is measured 3 times
before generating the final spectrum, which is a mean of
3 spectral intensities. The spectral resolution was ¾4 cm1.
We also found that there were no changes in the spectral
features of the tissues when repeated after 24 h. Data from
half the mice were used to build the discriminant function
model, while data from the other half were used to test the
model.
Before the data were subjected to statistical analysis,
they were cleaned from various types of noises. The data
processing steps included cosmic ray removal, subtraction
of noise, removal of tissue fluorescence (when present) and
normalization of the spectral intensities. A median filter was
applied to the raw data to eliminate any cosmic rays or
spikes in the data. Then noise was filtered using wavelets,20
which has been proved useful for de-noising and filtering of
Raman data. The background fluorescence was subtracted
from the de-noised spectra using a modified cubic-spline
algorithm that requires no a priori knowledge of the spectra.
This algorithm divides the spectra into N (a parameter
chosen before the analysis) equal windows and picks the
minimum intensity point in each window. The algorithm
then checks each of the N points to see if it is a local
minimum and discards it if it is not. Then the algorithm
adds the endpoints of the spectra to the remaining points.
These points will now serve as the control points (or node
locations) for the first pass of the curve fit. A piecewise
cubic Hermite interpolating polynomial is used to fit the
points. The fitted curve is subtracted from the de-noised
spectra to produce the corrected spectra. We check to see
if the corrected spectrum contains any negative values; if it
does, then we choose the minimum point of the corrected







Figure 1. Representative Raman spectra for various tissue types identified in this study using 785 nm as the excitation wavelength.
The various Raman intensities are from normal mammary glands contralateral side (a), tumor-cells-injected side (b), tumor (c), lymph
nodes contralateral side (e), lymph-node tumor-cells-injected side (f) and mastitis (d).
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set of control points. The process is re-iterated until there
are only non-negative values in the subtracted spectra. This
iterative method is employed to prevent any over-fitting of
the de-noised spectra, and finally the corrected spectrum
was normalized to unit intensity. For the data analysis
we used SSPS statistical packages on desktop computers.
Each Raman spectrum contains 1310 data points and we
collected more than 650 spectra, but used 650 in our statistical
analysis.
By definition, in the covariance matrix, the variables
that fluctuate significantly are the ones that contribute
significantly to the covariance matrix elements. In our spectra
we identified 44 Raman peaks and out of these peaks we
selected 29 peaks for statistical analysis on the basis of their
standard deviation values. For this selection we determined
the standard deviation of all the peaks over the whole data
set and took only those peaks whose standard deviation was
more than 15% of the maximum observed standard deviation
value.
The diagnosis of an altered tissue state, based upon
the Raman spectral variation, can involve examining the
presence/absence of peaks, peak heights and energy shifts
of several peaks. Accordingly, collection of large sample
size of data and application of multivariate statistical
procedures are required in order to make reliable predictions.
To reduce the number of variables, we applied principal
components analysis (PCA).21,22 This method mutually
correlates all the n variables of the data set by calculating
an n ð n dimensional correlation matrix. The original
variables are then combined into a smaller number of
principal components that are orthogonal to one another.
The orthogonal variables represent different states of the
tissue. At the end of the analysis the independent trends
present in the original data set can be easily observed in the
reduced variables space through a series of two-dimensional
graphs of the significant principal components.
Discriminant function analysis (DFA),23 which uses a
linear combination of independent variables to maximize
the separation among the different groups, was used as
a classification technique. Half the mice data were used
to develop the algorithm and the other half were used
to test the predicted classification against the pathologist’s
tissue assignments. Finally we used multivariate analysis of
variance (MANOVA) tests to determine whether there are
any significant differences among the tissues.
RESULTS AND DISCUSSION
Raman spectral signatures
The histological examinations of the tissues identified four
tissue types: normal mammary glands, mammary tumors,
mastitis (fat necrosis and inflammation in two mice), and
lymph nodes. Raman spectroscopy not only identified
these four tissues but in many instances also distinguished
mammary and lymph tissues from the injection side of the
Figure 2. The scatter plots of first two important principal
component scores, denoted by PC1 and PC2.
Figure 3. Scatter plots of first two important discriminant
functions plotted against one another.
mouse vs the contralateral side. Each tissue type showed
unique spectral features. As the tissue type changes (e.g.
lymph to tumor) most peaks in the Raman spectrum show a
variation in their intensities, though some are more dramatic
than others, leading to the unique diagnostic features noted
above. A typical spectrum for each pathological case as
identified by the histological examinations is shown in
Fig. 1. On the right-hand side of this figure are the photos
of corresponding normal, tumor, mastitis and lymph-node
tissues. It is interesting to note that the spectral features
of the normal mammary glands are remarkably similar to
those of normal human breast spectra.1 This shows that this
mice study may have direct implications to that of human
breast diseases. One sees a prominent Raman band around
1748 cm1 in the normal spectrum, but it is completely lost
in the tumor spectrum. This band is also absent in the
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Figure 4. (A) Error bar plot for PC1 against tissue types. The Raman signals for different tissue types are clearly different. (B) Error
bar plot for discriminant function 1 against tissue types.
lymph-node spectrum on the tumor-cells-injected side. Most
of Raman bands of the mastitis spectrum are broadened
compared to the normal spectrum.
Because of the tumor, the normal tissue exhibits several
changes and develops additional features as observed in the
Raman spectra: (1) The high-frequency mode at ¾1747 cm1
due to C O stretch of lipids nearly loses all its intensity
indicating the loss of lipid content in the tissue. (2) The band
at ¾1655 cm1 becomes broad and asymmetric toward the
high-frequency side. This is due to the emergence of the
amide I band of proteins. We estimate the position/s of
the additional band/s in the range 1660–1675 cm1, which
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are consistent with the protein ˛-helix, ˇ-sheet and random
coil structures. (3) Changes and increases in the intensity
profile are seen at ¾1265 cm1 (amide III region) along with
an additional band at ¾1002 cm1. (4) The low-frequency
bands due to tyrosine at ¾850 and 830 cm1 are seen with
increased intensity, although in the normal tissues there
are some low-intensity, broad peaks near these frequencies.
These changes indicate that the tissue identified as tumor
by pathology shows an increased level of protein and
drastically reduced levels of lipid in contrast to lipid-rich
normal tissue.
PCA transformed the initial 29-dimensional data into five
dimensions. First three eigenvectors capture 97% of the total
variance presence in the spectral data (Fig. 2). Tumors display
a very distinct pattern compared to other tissues and states.
This shows that at the biomolecular level major changes
have occurred in the normal mammary glands because
of tumor. Similarly, the spectra of mastitis, and those of
normal mammary gland on the contralateral and tumor-
cells-injected sides are also different from each other. From
this figure it is evident that there are strong fluctuations
in the concentrations of the biomolecules of the normal
tissue when it is transformed because of the cancer disease,
and Raman spectroscopy is sensitive enough to detect these
transformations.
Spectral features of mammary tumors and other
tissues
In the Fig. 3, discriminant function 1 is plotted against
discriminant function 2, resulting in most of the tumor
spectra being separated from the rest of the tissue types. The
only spectra tending to slightly mix with the tumor is from
the lymph nodes on the tumor-cells-injected side as marked
by the circles. The second most important result in Fig. 3 is
that the discriminant function 2 can clearly separate mastitis
from the other tissues. Figure 3 also shows some dispersion
of the lymph-node spectra. From this figure one observes
that normal mammary spectra from the contralateral side
are tightly clustered compared to others. These claims, that
the spectra of normal mammary glands, tumor, mastitis
and lymph nodes are statistically different, are further
strengthened in the error bar plots of PC1 and discriminant
function 1 against the tissue types as shown in Fig. 4(A) and
(B), respectively. From these figures one can clearly see that
the Raman signals for all the six different types of tissues are
different.
Spectral features of mastitis
DFA and PCA plots showed that spectral changes due to
mastitis are nearly as pronounced as those from tumor
whenever mastitis is present in the tissue. In our study we
found that 2 out of 11 mice showed mastitis and it was present
only on the tumor-injected-side mammary glands. Given a
strong correlation of mastitis and tumor, it is worthwhile
to investigate its spectral characteristics and see whether
Figure 5. The scatter plots of the first two important principal
components of the Raman spectra without including the
Raman data from tumor-cells-injected side.
Figure 6. The scatter plots of the first two important
discriminant functions against each other for the Raman data
without the Raman spectra from tumor-cells-injected side.
they strongly distinguish from normal and lymph nodes.
So we analyzed the Raman spectra of mastitis, normal
tissue samples and lymph nodes from both injected and
contralateral sides. The results of PCA are shown in Fig. 5.
In this analysis, the spectra of tumor tissues (confirmed
by pathological studies) were excluded from the data set.
Clearly mastitis show a very different trend compared to the
others and this trend is strongly projected in the DFA plots
shown in Fig. 6. In Fig. 7(A) and (B), we show the error bar
plot for PC1 and for discriminant function 1, respectively,
against the tissue types. One clearly sees that mastitis is very
different from the others. We believe that this type of Raman
spectral behavior is expected from a tissue in which cancer is
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not fully manifested yet but mastitis has already developed.
From Fig. 6 one observes that the normal mammary gland
spectra from the contralateral side are more clustered and
separated from most of the data of mammary glands from
the tumor-cells-injected side. The pathological or clinical
significance, if any, of the subclustering of mastitis is yet to
be resolved.
Surgical significance
Establishing the boundary between a tumor and the
normal parenchyma tissue of an organ is critical for
successful surgical removal. The separation between the
normal mammary spectra from tumor-cells-injected side
and contralateral sides is also seen in Fig. 7(B), which
shows the discriminant function 2 against the tissue types.
Figure 7. (A) The error bar plot for PC1 against different tissue types. This shows that the PC scores for all the five different tissue
types are statistically different. (B) The error bar plot for discriminant function 1 against different tissue types. This shows that the
discriminant scores for all the five different tissue types are statistically different.
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This distinction could be quite useful in precisely defining
surgical incision boundaries. Ultimately, one simply needs
to know whether a tissue being examined is cancerous or
not. Accordingly, we have collapsed our categories into two:
tumor and nontumor. For the data used to construct the
algorithm, we correctly classified 99.0% of the nontumor
tissue and 94.5% of the tumors were correctly classified. For
the data not used to construct the algorithm, we correctly
classified 92.2% as nontumorous. Thus, we have, at best,
7.9% false positive results. For the data used to construct
the algorithm, we correctly identified tumors 94.5% of the
time. And, for the data not used to construct the algorithm,
we correctly identified tumors 79.2% of the time resulting
in slightly more than 7.9% false positives. When we used
an expanded tissue designation to include mastitis, tumors
were correctly predicted 74.3% of the time, with 16.8% being
predicted to be mastitis and 6.9% predicted to be normal
mammary tissue.
CONCLUSIONS
We have demonstrated that Raman spectroscopy measure-
ments of mammary gland tissues from mice injected with
4T1 tumor cells can distinguish mammary tumors from
other physiological or pathological states of the mammary
glands. The diagnostic algorithms based on the Raman spec-
trum peak heights categorize tissues into six classes. Out
of these, tumor and mastitis are separated from the rest.
These separations are of vital clinical importance. However,
the spectra of normal mammary glands and lymph nodes
from the contralateral side overlap, but lymph-node spectra
from the tumor-cells-injected side show slight mixing with
tumor spectra. This study suggests that Raman spectroscopy
can possibly perform a real-time analysis of the human
mammary tissues for the detection of cancer.
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